Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma

We reported the therapeutic effects of TATI in four patients with advanced HCC. All patients underwent TACE treatment at the beginning of disease diagnosis. During follow-up, all patients were treated with microwave ablation because of a residual tumor or recurrence. For tumor control, apatinib, a TKI, was administered after ablation. If the tumor was resistant to the TKI, we continued to apatinib therapy in combination with immunotherapy (camrelizumab). All the four patients had better survival benefits and no serious adverse effects.

Source: Journal of Cancer Research and Therapeutics - May 27, 2020 Category: Cancer & Oncology Authors: Min Meng Wenhong Li Xia Yang Guanghui Huang Zhigang Wei Yang Ni Xiaoying Han Jiao Wang Xin Ye Source Type: research